Back to Search
Start Over
Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
- Source :
-
Blood [Blood] 2009 May 07; Vol. 113 (19), pp. 4521-4. Date of Electronic Publication: 2009 Feb 17. - Publication Year :
- 2009
-
Abstract
- Recent data highlight the importance of inflammatory markers during human immunodeficiency virus type 1 (HIV) infection. HIV-associated multicentric Castleman disease (HIV-MCD) presents with systemic symptoms attributed to cytokine disarray, and we have previously shown that the use of the anti-CD20 monoclonal antibody rituximab induces clinical remissions. Before and during successful rituximab therapy, 15 plasma cytokines were measured as were adaptive (CD4, CD8, CD19) and innate (CD16/56) immune cell populations and HIV-1 viral loads. A significant reduction from baseline of the CD19 B-cell count, consistent with rituximab's mechanism of action, was observed. Markedly elevated cytokine levels were observed before rituximab therapy, and a reduction from baseline values with rituximab therapy was observed for interleukin (IL)-5, IL-6, and IL-10. Therapies that reduce the inflammatory cytokine response are likely to be successful in a range of diseases, including HIV-MCD, and in the future may be used to guide therapeutic strategies.
- Subjects :
- Antibodies, Monoclonal, Murine-Derived
Antigens, CD20 immunology
Castleman Disease virology
HIV Infections blood
HIV Infections virology
Humans
Prognosis
Rituximab
Viral Load
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents therapeutic use
Castleman Disease blood
Castleman Disease drug therapy
Cytokines blood
HIV Infections complications
HIV-1 pathogenicity
Subjects
Details
- Language :
- English
- ISSN :
- 1528-0020
- Volume :
- 113
- Issue :
- 19
- Database :
- MEDLINE
- Journal :
- Blood
- Publication Type :
- Academic Journal
- Accession number :
- 19224759
- Full Text :
- https://doi.org/10.1182/blood-2008-12-197053